| Trial ID: | L0561 |
| Source ID: | NCT04542304
|
| Associated Drug: |
Metolazone
|
| Title: |
Efficacy of Diuretics in Kidney Disease
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease|End Stage Renal Disease
|
| Interventions: |
DRUG: Metolazone|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in urine output, average volume of urine produced in 24 hours, Change from baseline urine output at 1 week for each study arm | Secondary: Change in kidney clearance of uremic solutes, kidney clearance of uremic solutes in ml/min, Change from baseline kidney clearance of uremic solutes at 1 week for each study arm|Change in quality of life questionnaire score, Kidney Disease Quality of Life 36 Questionnaire (KDQOL36), Change from baseline quality of life score at 1 week for each study arm
|
| Sponsor/Collaborators: |
Sponsor: Stanford University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: SINGLE (PARTICIPANT)|Primary Purpose: OTHER
|
| Start Date: |
2021-03-01
|
| Completion Date: |
2024-07
|
| Results First Posted: |
|
| Last Update Posted: |
2022-10-03
|
| Locations: |
Stanford University, Palo Alto, California, 94304, United States|VA Palo Alto Health Care System, Palo Alto, California, 94304, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04542304
|
